Veos Pharmaceuticals is a science-driven biotech company developing clinically validated, natural health solutions for aging, performance, metabolism, and immunity.
Our pipeline includes:
ThymoTropin™ – the world’s first natural myostatin-regulating ingredient for muscle health, sarcopenia, and GLP-1-associated muscle loss., StroVia™ – a natural metabolism and strength-enhancing formula now commercially launched in Canada., OliQuell™ – a patented olive-waste-based functional platform for air purification and circular economy applications., BioPropello™ – a biostimulant improving protein synthesis and stress resilience in agriculture.
Veos is GMP-compliant, IP-driven, and regulatory-ready, with active approvals under GRAS, EFSA, and Health Canada. Our business model is B2B licensing, partnering with global leaders in consumer health, pharma, and food.
We are operational in North America, the EU, and expanding into Asia through strategic alliances
Dr. Bassam Damaj is a biotech entrepreneur and pharmaceutical innovator with over 25 years of experience building science-based ventures.
He has founded 7 companies, led 3 IPOs, and raised over $500M across the U.S., EU, and MENA.
As CEO of Veos Pharmaceuticals, he leads the development of ThymoTropin™, the first natural and clinically validated myostatin regulator, designed to combat sarcopenia by preserving muscle growth, strength, and endurance in aging populations.
His expertise spans biotechnology, functional ingredients, clinical development, and global strategic partnerships — with a focus on healthy aging and longevity.